Lab-Grown Liver Tissue: A New Hope for Treating Liver Disease?
"Stem cell-derived 'mini-livers' show promise for research and potential future therapies."
In a recent issue of Archives of Toxicology, Hassan Rashidi and his team from the University of Edinburgh unveiled a study detailing the creation of 3D liver tissue spheroids derived from pluripotent stem cells. These spheroids, essentially miniature versions of liver tissue, hold immense potential for advancing our understanding and treatment of liver diseases.
The team utilized various human pluripotent stem cell lines, including H9, Man12, FSPS13B, and P106, to generate these 3D structures. The process involved differentiating the stem cells into hepatoblasts (precursor liver cells) and then further into hepatocyte-like cells (HLCs) using specific growth factors (HGF and OSM) in a culture environment that encouraged spheroid formation. These spheroids could be maintained in the lab for up to a year, showcasing their stability and potential for long-term study.
The resulting spheroids exhibited high expression of key liver proteins like HNF4A and albumin, confirming their liver-like characteristics. Importantly, the expression of specific liver enzymes (CYP3A4, SULT1, and MRP1) was observed primarily in the periphery of the spheroids, mirroring certain aspects of liver tissue organization. The success of this method across different stem cell lines (hESC and hiPSC) further strengthens its potential for wider application.
Liver Disease: A Growing Global Burden
Liver disease is a major health concern worldwide, affecting millions of people each year and accounting for a substantial share of global mortality. Because precise figures vary widely by region, registry, and definition, it is difficult to state a single reliable statistic for the total burden of chronic liver disease. What is clear is that cirrhosis, liver failure, and liver cancer remain among the leading causes of death and that current treatment options are limited. This is the backdrop against which researchers are pursuing lab-grown liver tissue and cell-based regenerative approaches as new hope.
Today's Standard Treatments and Their Limits
For advanced liver disease, the accepted standard of care centers on managing complications and, in the most severe cases, liver transplantation. Drug therapies can slow progression and manage symptoms, but they generally cannot restore lost liver function. Liver transplantation, while effective, is limited by donor shortages, high cost, and the need for lifelong immunosuppression. These constraints have driven interest in alternatives, including lab-grown liver tissue and stem cell therapies, though such approaches are still early in development.
From Liver Stem Cells to Modern Cell Therapy
The foundational concept is that liver stem cells are called upon to regenerate the liver parenchyma when the ability of ordinary hepatocyte proliferation is compromised. Over the years, a wealth of knowledge has accumulated about the cellular and molecular events of liver stem cell activation and differentiation across animal models and human liver diseases. A comprehensive timeline charting the field from 1868 to 2026 traces stem cell science from the first use of the term to today's approved cell therapies. Looking forward, researchers view human pluripotent stem cell-derived cells, chemically induced liver progenitors, and 'liver' organoids as holding great promise for building new cell therapies for acute and chronic liver diseases.
Why are Liver Spheroids a Big Deal?
The creation of these liver spheroids addresses a critical need in the field of liver research. For years, scientists have been working to develop reliable in vitro (lab-based) systems for studying liver function and toxicity. Traditional methods often fall short of accurately replicating the complexity of the human liver, making it difficult to predict how drugs and other substances will affect the organ in vivo (in a living organism).
- Improved Liver Function: 3D structures allow cells to interact with each other in a more natural way, leading to better representation of liver-specific functions like metabolism and enzyme induction.
- Long-Term Studies: The ability to maintain these spheroids for extended periods (up to a year) enables long-term toxicity studies and investigations into chronic liver diseases.
- Omics Applications: Spheroids can be used for advanced “omics” studies (genomics, proteomics, metabolomics) to analyze the effects of various compounds on liver cells at a molecular level.
- Personalized Medicine Potential: iPS cells from individuals with genetic liver diseases can be used to generate spheroids, creating models for studying and potentially treating these specific conditions.
MSCs and iPSC-Derived Hepatocytes Lead the Field
A systematic review and meta-analysis of randomized controlled clinical trials, published in April 2025, assessed the efficacy and safety of mesenchymal stem cell (MSC) therapy in acute-on-chronic liver failure and chronic liver disease. MSCs have attracted specific attention for end-stage liver disease because liver transplantation, though still the most effective treatment, is fraught with donor shortage, high cost, and immunosuppression. Meanwhile, a significant focus of current progress centers on generating functional hepatocytes from induced pluripotent stem cells (iPSCs), opening up new possibilities for regenerative therapies in liver disease. Taken together, these lines of research indicate that MSCs and iPSC-derived cells are among the leading candidates for next-generation liver treatments.
Unstandardized Protocols and Unproven Benefits
A key criticism, reported in a 2019 review, is that stem cell therapy in liver failure is not yet standardized, with every center using its own methods, which complicates comparison of results across studies. Beyond the lack of standardization, cautious observers emphasize that benefits must be weighed against risks for a disease that one source reports causes over 33,500 deaths annually in the U.S. Even favorable assessments ground MSC therapy's promise in its immunomodulatory, anti-fibrotic, and regenerative capabilities rather than in proven outcomes. The overarching caution is that promising early results have not yet translated into a uniformly accepted, evidence-backed standard of care.
Cell Therapy Versus Transplantation
Comparisons between cell-based treatments and conventional care for liver disease remain difficult to draw with confidence, since head-to-head trials are limited and protocols vary widely. In broad terms, stem cell and tissue-engineering approaches may offer advantages over transplantation, such as avoiding donor shortages and lifelong immunosuppression. However, they come with their own uncertainties around durability, cell engraftment, and long-term safety. Until larger, more standardized studies accumulate, claims of superiority over accepted treatments should be treated as preliminary rather than settled.
Future Directions: From Lab to Clinic?
The development of liver spheroids represents a significant advancement in liver research, offering a more realistic and versatile model for studying liver function, toxicity, and disease.
The Most Rigorous Evidence Calls for Caution
The most rigorous appraisals to date remain measured. A GRADE-based systematic review and meta-analysis published in June 2026 concluded that current evidence offers very low certainty regarding the efficacy of stem cell therapies for liver cirrhosis and acute-on-chronic liver failure. A separate comprehensive meta-analysis of stem cell therapy for liver failure reached similarly restrained conclusions, treating early trial results as encouraging but not definitive. Both reviews agree that further high-quality research is necessary to clarify the role of stem cells in treating liver diseases and to ensure both safety and efficacy before broad clinical adoption.
ATMPs and Next-Generation Cell Platforms
Looking ahead, innovative cell-based platforms for liver regeneration include advanced therapy medicinal products (ATMPs) based on mesenchymal stem cells, developed in response to gastrointestinal and liver diseases remaining major contributors to global morbidity and mortality with limited curative or regenerative options. Stem cell therapy is increasingly positioned as a promising alternative to liver transplantation for advanced cases, with clinical studies underway exploring stem cells from various sources. However, because of the variability among current studies, further validation is needed to establish the safety and effectiveness of stem cell therapy, and researchers must work to standardize how these treatments are delivered and measured.
Regulation, Cost, and Access
Bringing lab-grown liver tissue from the bench to the bedside involves challenges that go beyond biology, including regulatory approval, manufacturing at scale, and cost. The absence of standardized protocols noted across the literature makes it harder for regulators and insurers to evaluate and cover these treatments consistently. Equitable access will also depend on whether therapies can be delivered affordably to the people who need them most, in regions where liver disease burden is highest. These systemic issues will need to be resolved alongside the science if regenerative approaches are to fulfill their promise.
Case Reports and Early Patient Experiences
Real-world application has begun cautiously. In one case reported in the literature, mesenchymal stem cell transplantation was performed on a 50-year-old male with decompensated liver disease as an alternative to liver transplantation, though its efficacy remains uncertain. Encouraging signals from adjacent fields also matter here: a late-stage multinational clinical trial involving 315 patients with advanced heart failure found that stem cell-based therapy improved patients' quality of life, with lower death and hospitalization rates. Such accounts humanize the research data while underscoring that long-term benefit in liver disease specifically is still being established.
However, further research is needed to fully characterize these HLCs and optimize their differentiation to more closely resemble primary human hepatocytes. Specifically, future studies should focus on:
Determining whether the supportive effect of HLC-spheroids in mouse models of partial hepatectomy have a clinical perspective, and if this may lead to applications for transplants.